Charles Liu

Charles Liu, PhD, is a Senior Product Manager at Cytel. Before joining Cytel in 2012, he was a postdoctoral fellow at Boston University. His current research interests include: Enrollment & events prediction, Go/No-Go decision making, and Program & Portfolio optimization.

Recent Posts

Best Sample Size Calculators for iPhone

Posted by Charles Liu

Mar 6, 2018 12:05:25 PM

Photo by Dose Media on Unsplash

By Charles Liu, Senior Product Manager, Cytel

Several years ago, I was one of few Luddites in my social circle still using a “dumb” phone. Other than calls, and (text only!) messaging, it had no other functionality. Once I made the switch, a whole new magical world unveiled itself. With the tap of a button, I could read my email, listen to a podcast, find a...

Read More

Topics: Trial Design Software, EAST 6.4, Sample Size


3 Questions to Ask About Your Trial's Enrollment

Posted by Charles Liu

Jul 2, 2015 1:33:01 PM

 

Clyde Haberman, a columnist for the New York Times, once commented on the remarkable consistency of train arrival times on the Tokyo subway: "Every station lists the scheduled arrival times: 9:01, 9:04, 9:08 and so on. I lived in that city for five years...I never saw a train arrive so much as a minute late, not once. A posting of 9:01 meant 9:01." [1]. Such predictability is rarely observed in...

Read More

Topics: feasibility studies, patient enrollment, enforesys


Patient Recruitment Feasibility: Would you bet $12 million dollars on it?

Posted by Charles Liu

Jun 4, 2015 3:11:26 PM

Two insightful papers from Applied Clinical Trials should be of interest to many clinical trial planners. The first by Kenneth Getz describes the problem of enrollment performance, while the second by Matthew Kibby proposes a potential solution. The Facts

Getz reports a study providing recent estimates of industry-wide rates of enrollment delays [1]. In 2012, the Tufts Center for the Study...

Read More

Topics: feasibility studies, patient enrollment, enforesys


Bayesian Trial Designs are Safe, Efficient & Flexible: A Review of Published Phase 1 Studies

Posted by Charles Liu

Aug 21, 2014 10:03:33 AM

 

 

Use of the continual reassessment method (CRM) is safe, efficient, and flexible, according to a comprehensive review of 53 published Phase I trials from 2003-2013. The review, just published in the Journal of Clinical Oncology by leading researchers Iasonas and O'Quigley, challenges common misconceptions about model-based dose escalation designs.

Read More

Topics: Dose-Escalation, CRM, Phase 1


Cytel Animation: Modern Dose Escalation Phase 1 Trials

Posted by Charles Liu

Jul 15, 2014 8:00:00 AM

 

Learn More about East ESCALATE

Do you design or analyze Phase 1 dose escalation trials? Have you considered methods other than 3+3? This new Cytel video demonstrates how East ESCALATE can help you to explore your options. 

Read More

Topics: Dose-Escalation, Bayesian Methods, Cytel Videos


Powering Oncology Trials for Success: Adaptive Designs in East

Posted by Charles Liu

Jun 5, 2014 9:37:00 AM

Charles Liu, PhD, Cytel Statistician and Product Manager

In the US, cancer is the most common cause of death after heart disease, accounting for nearly 1 of every 4 deaths [1]. Tackling the immense burden of this disease, researchers are currently investigating an estimated 900 novel cancer agents in over 6,000 clinical trials [2]. Unfortunately, the clinical success rate remains low, and failed...

Read More

Topics: Oncology, Education, Adaptive Clinical Trials


The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.

 

Posts by Topic

see all

Recent Posts